92 results on '"Carson, Peter"'
Search Results
2. MP-453090-7 IDENTIFYING PATIENTS WITH LVEF≤55% WHO MAY BENEFIT FROM A PRIMARY PREVENTION ICD USING SEATTLE PROPORTIONAL RISK MODEL FOR MILDLY REDUCED EF (SPRM-MR) IN 14,752 PATIENTS
3. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
4. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
5. Is The Benefit Of CardioMEMS Lessened In Elderly Patients With Heart Failure?
6. Treatment of HF in an Era of Multiple Therapies
7. Cause of Death in Patients With Acute Heart Failure
8. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
9. Conduct of Clinical Trials in the Era of COVID-19
10. Adjudication Of Cause-specific Endpoints In Heart Failure Trials
11. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction
12. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development
13. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy
14. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
15. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
16. OPTIMAL MEDICAL THERAPY USE AND LONG-TERM OUTCOMES IN CABG-ELIGIBLE HEART FAILURE PATIENTS: INSIGHTS FROM THE STICH TRIAL
17. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
18. Trying to Make Progress on Survival in a Complicated Area
19. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium
20. Redefining “Winning” and Its Implications in Heart Failure Clinical Trials ∗
21. Natriuretic Peptide Levels and Interaction With Treatment in HFpEF
22. Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from the ADMIRE-HF Trial)
23. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction
24. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model
25. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee
26. Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure
27. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee
28. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction
29. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
30. MARKERS OF EXTRACELLULAR MATRIX TURNOVER AND RISK OF DEATH IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: RESULTS FROM I-PRESERVE
31. Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment
32. The STICH Trial (Surgical Treatment for Ischemic Heart Failure)
33. Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy
34. Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research
35. Association Between Bilirubin and Mode of Death in Severe Systolic Heart Failure
36. MORBIDITY AND MORTALITY IN DIABETICS WITH HEART FAILURE AND A PRESERVED EJECTION FRACTION: RESULTS FROM THE I-PRESERVE TRIAL
37. Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee
38. IMPACT OF REMOTE, WIRELESS PULMONARY ARTERY HEMODYNAMIC MONITORING IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE: INSIGHTS FROM THE CHAMPION TRIAL
39. Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee
40. Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes
41. Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure
42. Influence of Global Region on Outcomes in Heart Failure Beta-Blocker Trials
43. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure
44. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure
45. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])
46. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program
47. PERIPHERAL COLLAGEN MARKERS PREDICT ALL-CAUSE MORTALITY AND CARDIOVASCULAR HOSPITALISATION IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS OF THE I-PRESERVE COLLAGEN SUB-STUDY
48. BASELINE SYSTOLIC BLOOD PRESSURE AND OUTCOMES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION - RESULTS FROM THE I-PRESERVE TRIAL
49. ACUTE CORONARY SYNDROMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: A HARBINGER OF DEATH?
50. HEART FAILURE WITH PRESERVED EJECTION FRACTION: MORTALITY RISK POST FIRST HOSPITALIZATION - DATA FROM I-PRESERVE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.